Cullinan Therapeutics, Inc. (CGEM) NASDAQ
15.56
-0.65(-4.01%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
15.56
-0.65(-4.01%)
Currency In USD
| Previous Close | 16.21 |
| Open | 15.89 |
| Day High | 16 |
| Day Low | 15.25 |
| 52-Week High | 16.74 |
| 52-Week Low | 5.68 |
| Volume | 772,956.71 |
| Average Volume | 876,984 |
| Market Cap | 956.29M |
| PE | -4.62 |
| EPS | -3.37 |
| Moving Average 50 Days | 14.43 |
| Moving Average 200 Days | 11.02 |
| Change | -0.65 |
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
GlobeNewswire Inc.
Feb 18, 2026 12:00 PM GMT
CAMBRIDGE, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 05, 2026 12:00 PM GMT
CAMBRIDGE, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended Phase 2 dose for CLN-049 pivotal registrational